Overall Survival Improved with Adjuvant Osimertinib in Resected EGFR-Mutated NSCLC
1. The 5-year overall survival had a hazard ratio of 0.49, and this benefit was generally consistent across subgroups (stage,...
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
1. The probability of progression-free survival at 12 months was 0.57 in the experimental group (cabozantinib plus nivolumab and ipilimumab)...
Trifluridine–Tipiracil and Bevacizumab Improves Survival in Metastatic Pretreated Colorectal Cancer
1. The median overall survival was 10.8 months in the combination group (FTD–TPI + bevacizumab) and 7.5 months in the...
Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation
1. The overall objective response rate was 35.1% in patients with initial measurable disease, all of which were partial responses,...
![Macitentan better than placebo for preventing progression of pulmonary arterial hypertension [SERAPHIN Trial]](https://www.2minutemedicine.com/wp-content/uploads/2013/08/ca68dc0329bef0b42ccae7b6656a0f_gallery-350x250.jpg)
Long-Term Outcomes of Sotorasib in KRAS-G12C Non–Small-Cell Lung Cancer
1. Sotorasib showed prolonged efficacy with a median OS of 12.5 months (33% at 24 months) and an ORR of...
Tislelizumab for advanced esophageal squamous cell carcinoma
1. Median overall survival was 17.2 months in the tislelizumab group versus 10.6 months in the placebo group (HR 0.66)....
CAR-T Cell Therapy for Relapsed or Refractory High-Risk Neuroblastoma
1. GD2-CART01 infusion had an overall response of 63% of patients (33% complete response) with a 3-year overall survival of...
Belzutifan plus cabozantinib for immunotherapy pre-treated advanced renal cell carcinoma
1.The objective response rate was 30.8% with the majority attributing to partial response. 2. Most common adverse events (grade 3...
Helicobacter pylori, Homologous Recombination Genes, and Risk of Gastric Cancer
1. The following genes had statistically significant increased odds ratio of gastric cancer; BRCA2, ATM, BRCA1, MLH1, PALB2, APC, MSH6,...
Alternative Dose Regimens of Exemestane in Postmenopausal Women with Breast Cancer
1. Through the reduction in serum estradiol, there was noninferiority between the 3-times-weekly vs once-daily dosage among compliant participants (PP...
